ArticleMalaysian orthopaedic journal2026
Comparison of Outcome Between Neoadjuvant Chemotherapy with Limb Salvage Surgery and Amputation with Chemotherapy in Osteosarcoma Patients: A Systematic Review.
Article in Malaysian orthopaedic journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Osteosarcoma is a rare malignant bone tumour arising from primitive mesenchymal tissue, most often affecting males aged 10-30. Historically, treatment involved amputation or disarticulation, with a 5-year overall survival rate of just 20%. Materials and methods: This systematic review included studies from MEDLINE, Cochrane, EMBASE, and Google Scholar. Additionally, reference lists of relevant sources were manually reviewed. The search, conducted through 2021, used terms such as amputation, osteosarcoma, bone cancer, recurrence, and metastasis. Results: Eight relevant studies were thoroughly reviewed, most conducted at single institutions and published between 1990 and 2019, covering data from 1983 to 2015 and involving 1,389 patients. Three studies (646 patients) assessed 5-year disease-free survival (DFS) in limb osteosarcoma, reporting a median DFS of 56.9 months (range: 6-78 months). Five studies (969 patients) analysed local recurrence, showing higher relapse rates with limb salvage surgery (LSS) compared to amputation (73.5% vs. 28.1%). Additionally, six studies (1,141 patients) evaluated 5-year overall survival, with better outcomes in the LSS group (351 survivors) compared to the amputation group (248 survivors). Conclusion: In conclusion, this thorough review makes a valuable contribution to the current understanding of survival and local recurrence outcomes in patients with limb osteosarcoma treated with either LSS or amputation. The findings suggest that LSS is associated with a higher 5-year survival rate compared to amputation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.